Olfactory Stimulation in Severe Brain Injury

Effects of Olfactory Stimulation in Patients with Severe Acquired Brain Injury

The management of patients with disorders of consciousness (DoC) represents a topic of great importance and topicality in the medical-scientific field because of the complexity and extent of associated disabilities and the difficulty in identifying effective therapeutic approaches. Despite significant advances in neuroscience, much remains to be elucidated about the mechanisms that regulate consciousness, and which of these to act on to stimulate plasticity and thus promote responsiveness and functional recovery in patients. Evidence on treatments that promote arousal and communication skills in individuals with DoC is still limited.

Among the possible interventions proposed in the literature, sensory stimulation would act by stimulating synaptic plasticity, counteracting the sensory deprivation to which these patients are exposed.

Published studies on the topic have produced results that are not unique and difficult to compare across different stimulation protocols (content, intensity, frequency, modality), settings and patient populations.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Smell is a primitive and complex sense related to emotions, memory and language. When we smell an odor, its molecules reach the nasal cavity and bind to the receptors of olfactory neurons, which transform the chemical information into an electrical signal that reaches the olfactory bulb and is then transmitted to the brain areas (piriform cortex, amygdala, thalamus, hypothalamus, insula, anterior cingulate cortex, orbitofrontal cortex) deputed to the emotional perception of smell and its storage. Studies in the literature have demonstrated the ability of the olfactory stimulus to influence emotional and cognitive processes (attention, memory, language), motor gesture, and autonomic nervous system response in healthy subjects. The use of stimuli with emotional and familiar content for the subject has also been shown to increase the likelihood of observing a behavioral response in patients with DoC.

In DoC patients, the use of the olfactory stimulus (intensity, modality, timing, measurement tools) in the recovery process is still limited, and it has not yet been clarified what effect it has on awakening and neurovegetative nervous system response.

This study aims to investigate, in both healthy subjects and patients with obsessive compulsive disorder (DoC) resulting from severe Acquired Brain Injury (sABI), the effects that odors of various types produce at the level of the autonomic nervous system (ANS) and brain connectivity.

More specifically, this study aims to evaluate, in healthy subjects and in patients with DoC, the effects of neutral, pleasant, and unpleasant olfactory stimuli on ANS, brain connectivity, reactivity, and the possible onset of habituation following repeated administration of the same olfactory stimulus.

Study Type

Interventional

Enrollment (Actual)

24

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • RM
      • Roma, RM, Italy, 00168
        • Fondazione Policlinico Universitario A. Gemelli IRCCS

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 90 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Age between 18 and 90 years;
  • Glasgow Come Scale (GCS) score between 8 and 13;
  • Level of Cognitive Function (LCF) score between 2 and 3;
  • Latency from the acute event of not more than 2 months;
  • Spontaneous eye opening.

Exclusion Criteria:

  • Documented history of brain injury prior to the one that resulted in hospitalization;
  • Documented history of uncorrected visual or hearing impairment;
  • Documented history of chronic rhinosinusitis with or without the presence of naso-sinus polyps;
  • Previous history of psychiatric and/or neurological disorders that resulted in significant disability prior to the acute event;
  • Acute pathology at the time of recruitment, head injury, or ischemic or expansive injury with suspected peripheral olfactory tract involvement.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group natural_neutral_chemical

The recruited subjects (DoC patients and healthy subjects) will be evaluated inside a quiet, well-ventilated room and will be subjected to olfactory stimulation using odors with different characteristics a "natural" type odor, e.g., mint, a "chemical" type odor, e.g., gasoline, and a "neutral" type odor, e.g., water.

Stimulation will have, for each odor the duration of 5 minutes. It will always be carried out within the same time slot (between 8:00 am and 4:00 pm) for 5 consecutive days for 2 weeks. Before and after the administration of each odor, a neutral odor (water) will be administered as a control in the same manner as described above.

The sequence of odor administration will be: natural odor (mint) for 5 minutes, neutral odor (water) for 5 minutes, chemical odor (gasoline) for 5 minutes.

The odors being tested (natural odor, neutral odor, chemical odor) are part of the 40 fragrances made by International Flavors and Fragrances (IFF) and each is contained in an approximately 15-mL glass bottle. The selected odors will be administered using a small paper strip (15 cm length and 0.7 cm width) that will be soaked in the selected odor and placed under the subject's nose at a minimum distance to prevent direct contact of the strip with the skin; the strip will be moved alternately from one nostril to the other.

Stimulation will have, for each odor the duration of 5 minutes. It will always be carried out within the same time slot (between 8:00 am and 4:00 pm) for 5 consecutive days for 2 weeks. Before and after the administration of each odor, a neutral odor (water) will be administered as a control in the same manner as described above.

The sequence of odor administration will be randomized according to a computer-generated sequence.

Experimental: Group chemical:neutral_natural

The recruited subjects (DoC patients and healthy subjects) will be evaluated inside a quiet, well-ventilated room and will be subjected to olfactory stimulation using odors with different characteristics a "natural" type odor, e.g., mint, a "chemical" type odor, e.g., gasoline, and a "neutral" type odor, e.g., water.

Stimulation will have, for each odor the duration of 5 minutes. It will always be carried out within the same time slot (between 8:00 am and 4:00 pm) for 5 consecutive days for 2 weeks. Before and after the administration of each odor, a neutral odor (water) will be administered as a control in the same manner as described above.

The sequence of odor administration will be: chemical odor (gasoline) for 5 minutes, neutral odor (water) for 5 minutes, natural odor (mint) for 5 minutes.

The odors being tested (natural odor, neutral odor, chemical odor) are part of the 40 fragrances made by International Flavors and Fragrances (IFF) and each is contained in an approximately 15-mL glass bottle. The selected odors will be administered using a small paper strip (15 cm length and 0.7 cm width) that will be soaked in the selected odor and placed under the subject's nose at a minimum distance to prevent direct contact of the strip with the skin; the strip will be moved alternately from one nostril to the other.

Stimulation will have, for each odor the duration of 5 minutes. It will always be carried out within the same time slot (between 8:00 am and 4:00 pm) for 5 consecutive days for 2 weeks. Before and after the administration of each odor, a neutral odor (water) will be administered as a control in the same manner as described above.

The sequence of odor administration will be randomized according to a computer-generated sequence.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sympathetic Skin Response (SSR)
Time Frame: Change from baseline SSR at 2 weeks
SSR is a physiologic measurement to record the electrical potential through an electrode placed on the palm of the hand after median nerve stimulation. The test is based on the temporary change in skin electrical resistance in response to activation of the sweat glands when exposed to a stimulus. It allows assessment of the ANS response through the study of sympathetic cholinergic efferent pathways
Change from baseline SSR at 2 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Heart Rate Variability (HRV)
Time Frame: Change from baseline HRV at 2 weeks
HRV, that is, the assessment of heart rate variability, is evaluated using an electrocardiographic (ECG) device with normal surface electrodes applied at the level of the heart and special software for data analysis.
Change from baseline HRV at 2 weeks
Electrodermal Activity (EDA)
Time Frame: Change from baseline EDA at 2 weeks

The E4 wereable medical devide (Empatica) will be used to assess the electrodermal activity (EDA).

Fluctuations in some electrical properties of the skin will be recorded; the online software Empatica (https://www.empatica.com/en-eu/) will the export the recorded data.

A higher EDA value corresponds to a higher stress level.

Change from baseline EDA at 2 weeks
Electrocortical activity
Time Frame: Change from baseline EEG-HD at 2 weeks
The information inherent in the assessment of electrocortical activity, will be recorded using 64-channel high density electroencephalogram (EEG-HD). The presence of a cortical potential in motor area will be assessed by following the somatotopic organization, by reconstructing a brain map in amplitude.
Change from baseline EEG-HD at 2 weeks
Coma Recovery Scale-revised
Time Frame: Change from baseline CRS-r at 2 weeks

CRS-r is an assessment tool that examines 6 functions: auditory, visual, oral-verbal motor, communicative and vigilance.

Its different items are organized hierarchically (low scores represent reflex activities, hig scores decribe cognitively mediated behaviours).

For each function examined, the diagnosis of Vegetative State, Minimal Consciousness State, Emergence from Minimal Consciousness State can be made.

Change from baseline CRS-r at 2 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Luca Padua, MD, phD, Fondazione Policlinico Universitario A. Gemelli, IRCCS

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 15, 2021

Primary Completion (Actual)

April 30, 2022

Study Completion (Actual)

June 30, 2024

Study Registration Dates

First Submitted

February 17, 2023

First Submitted That Met QC Criteria

February 17, 2023

First Posted (Actual)

February 28, 2023

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

March 19, 2025

Last Verified

February 1, 2024

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Disorder of Consciousness

Clinical Trials on Olfactory sstimulation

Subscribe